Search

Showing 50 results for your search "Comtess".

Research areas

Central nervous system medicines The central nervous system therapy area includes drugs for the ... Orion’s R&D. Orion’s most successful proprietary drugs, Comtess® and Stalevo®, are the result of these

Prescription drugs and self-care products

Our product portfolio includes: Proprietary drugs developed by Orion itself Substitutable generic ... Precedex® dexmedetomidine intensive care sedative 1999 Comtess®/Comtan® entacapone Parkinson’s disease

Market reviews 2017

branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about 10% ... branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about 10%

Outlook for 2009

other European countries. Global in-market sales of Comtess/Comtan and Stalevo drugs will show further ... European countries. Global in-market sales of the Comtess/Comtan and Stalevo drugs will show further

Market reviews 2016

branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for slightly over ... branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for under 15%

Market reviews 2013

branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-fifth ... branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about a quarter

Market reviews 2007

(10%). The global audited sales of Orion’s Stalevo® and Comtess®/Comtan®, were EUR 348.1 (285.5) million ... Stalevo accounted for EUR 144.3 (146.6) million and Comtess/Comtan for EUR 145.2 (144.3) million.

Market reviews 2015

branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for less than ... branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-sixth

CEO Timo Lappalainen’s reviews 2013

ago as expected. Total sales generated by Stalevo® and Comtess® products in Orion’s own sales organisation ... period of 2012. Total sales generated by Stalevo® and Comtess® products in Orion’s own sales organisation

CEO Timo Lappalainen's reviews 2017

expected, sales of Orion’s branded Parkinson’s drugs Stalevo, Comtess and Comtan declined, but growth especially ... expected, sales of Orion’s branded Parkinson’s drugs Stalevo, Comtess and Comtan declined, but growth in the

Market reviews 2014

branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for about one-sixth ... branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for nearly one-fifth

Orion Group Interim Report 1-3/2007

(10%). The global audited sales of Orion's Stalevo® and Comtess®/Comtan®, were EUR 348.1 (285.5) million ... Stalevo accounted for EUR 144.3 (146.6) million and Comtess/Comtan for EUR 145.2 (144.3) million.  

Market reviews

branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for 9% (11%) ... branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for 10% of the

Orion Group Interim Report January-June 2014

clearly lower than a year ago. Total sales of Stalevo® and Comtess® through Orion's own sales organisation ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report January-March 2015

Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs ... of products in the portfolio other than Stalevo® and Comtess®/Comtan® and excluding milestone payments

Orion Group Interim Report January-September 2015

sales of products in the portfolio other than Stalevo®, Comtess®/Comtan® and Precedex®, and excluding milestone ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report January-March 2014

than a year ago. Total sales generated by Stalevo® and Comtess® in Orion's own sales organisation were ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

CEO Timo Lappalainen's reviews 2014

clearly lower than a year ago. Total sales of Stalevo® and Comtess® through Orion’s own sales organisation ... than a year ago. Total sales generated by Stalevo® and Comtess® in Orion’s own sales organisation were

CEO Timo Lappalainen's reviews 2011

Published on 7 February 2012 “Strong year for Orion” “Our net sales and operating profit were ... sales of the product family and sales of Stalevo® and Comtess® through Orion’s own marketing were slightly

CEO Timo Lappalainen’s reviews 2008

Published on 6 February 2009 "Steady growth continued" “The net sales of the Orion ... combined sales of the Parkinson’s drugs Stalevo and Comtess, marketed through Orion’s own sales organisation

CEO's reviews 2007

"Profits remained at a good level" CEO Timo Lappalainen's review, published on ... strong growth is continuing in the sales of Stalevo® and Comtess® /Comtan® for Parkinson’s Disease." "All

Orion Group Interim Report January-September 2016

commenced. Sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan continued to decline, but more ... sales of products in the portfolio other than Stalevo®, Comtess®/Comtan® and Precedex®, and excluding milestone

Orion Group Half-Yearly Report January-June 2016

in sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan. In Europe generic competition ... sales of products in the portfolio other than Stalevo®, Comtess®/Comtan® and Precedex®, and excluding milestone

Orion Group Interim Report January-March 2016

in sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan due to generic competition. ... sales of products in the portfolio other than Stalevo®, Comtess®/Comtan® and Precedex®, and excluding milestone

Orion Group Interim Report January-June 2009

essentially the same. The key patents for the Stalevo and Comtess/Comtan drugs, which generate approximately ... drugs, Stalevo® (carbidopa, entacapone and levodopa) and Comtess®/Comtan® (entacapone), totalled EUR 123

Orion Group Interim Report January-June 2015

of products in the portfolio other than Stalevo® and Comtess®/Comtan® and excluding milestone payments ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Financial Statement Release for 2011

sales of the product family and sales of Stalevo® and Comtess® through Orion's own marketing were slightly ... with the equity ratio at least 50% Sales of Stalevo® and Comtess®/Comtan® currently account for approximately

Orion Group Interim Report 1-9/2008

combined sales of the Parkinson's drugs Stalevo and Comtess, marketed through Orion's own sales organisation ... drugs, Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone), totalled EUR 155

CEO Timo Lappalainen's reviews 2010

Published on 9 February 2011 “Good progress continued throughout the year” “Orion’s net sales ... strongly and clearly faster than sales of Stalevo and Comtess/Comtan. Simdax performed well in Southern

Orion Group Interim Report January-September 2014

Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs ... of products in the portfolio other than Stalevo® and Comtess®/Comtan® and excluding significant milestone

Orion Group Financial Statement Release for 2013

ago as expected. Total sales generated by Stalevo® and Comtess® products in Orion's own sales organisation ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report January-March 2013

continued to decline. Total sales generated by Stalevo® and Comtess® in Orion's own sales organisation were ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report January-June 2013

further declined. Total sales generated by Stalevo® and Comtess® products in Orion's own sales organisation ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report 1-6/2008

The net sales from the Parkinson's drugs, Stalevo® and Comtess®/Comtan®, totalled EUR 105.2 (102.0) million ... in-market sales of the Parkinson's drugs, Stalevo and Comtess/Comtan, in 2007 was under 15%, which is lower

Orion Group Interim Report January-March 2010

strongly and clearly faster than sales of Stalevo and Comtess/Comtan. Simdax performed well in Southern ... Orion's Stalevo® (carbidopa, entacapone and levodopa) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report 1-3/2009

drugs, Stalevo® (carbidopa, entacapone and levodopa) and Comtess®/Comtan® (entacapone), totalled EUR 62.2 ... European countries. Global in-market sales of the Comtess/Comtan and Stalevo drugs will show further

Orion Group Interim Report January-March 2017

expected, sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan continued to decline, but growing ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Half-Year Financial Report January-June 2017

expected, sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan declined, but other growing ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report January-September 2017

expected, sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan declined, but growth in the ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Interim Report January-June 2011

Orion's Stalevo® (carbidopa, entacapone and levodopa) and Comtess®/Comtan® (entacapone) Parkinson's drugs ... equity ratio at least 50%   Sales of Stalevo® and Comtess®/Comtan® currently account for approximately

Orion Group Financial Statement Release for 2012

previous year. Total sales generated by Stalevo® and Comtess® in Orion's own sales organisation were ... Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs

Orion Group Financial Review of 2007

strong growth is continuing in the sales of Stalevo® and Comtess® /Comtan® for Parkinson's Disease.   ... Net sales from the Parkinson's medicines Stalevo and Comtess/Comtan totalled EUR 200.1 million (2006:

Orion Group Interim Report January-March 2011

Orion's Stalevo® (carbidopa, entacapone and levodopa) and Comtess®/Comtan® (entacapone) Parkinson's drugs ... with the equity ratio at least 50%Sales of Stalevo® and Comtess®/Comtan® currently account for approximately

Orion Group Interim Report January-September 2009

drugs Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) totalled EUR 182 ... other European countries. Global in-market sales of Comtess/Comtan and Stalevo drugs will show further

Orion Group Interim Report January-March 2012

Orion's Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs ... the equity ratio at least 50%  Sales of Stalevo® and Comtess®/Comtan® currently account for approximately

Orion Group Financial Statement Release for 2016

well. Sales of Orion's branded Parkinson's drugs Stalevo, Comtess and Comtan continued to decline, but more ... sales of products in the portfolio other than Stalevo®, Comtess®/Comtan® and Precedex®, and excluding milestone

Orion Group Interim Report 1-6/2007

medicines for Parkinson's Disease, i.e. Stalevo® and Comtess®/Comtan®, contributed EUR 102.0 (94.9) million ... Disease, Stalevo® (levodopa, entacapone, carbidopa) and Comtess®/Comtan® (entacapone) were EUR 102.0 (94

Orion Group Interim Report 1-9/2007

medicines for Parkinson's Disease, i.e. Stalevo® and Comtess®/Comtan®, contributed EUR 152.6 (137.2) ... Disease, i.e. Stalevo® (levodopa, entacapone, carbidopa) and Comtess®/Comtan® (entacapone) were EUR 152.6 (137

CEO Timo Lappalainen’s reviews 2012

Published on 5 February 2013 “Significant progress in Orion’s research projects” “Our net sales ... previous year. Total sales generated by Stalevo® and Comtess® in Orion’s own sales organisation were

CEO Timo Lappalainen’s reviews 2009

Published on 9 February 2010 "A successful year" "Orion’s net sales in 2009 ... essentially the same. The key patents for the Stalevo and Comtess/Comtan drugs, which generate approximately